Gilead Sciences

Amgen

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

IQVIA Hlds

Alnylam Pharmaceuticals

Mettler-Toledo

Waters

Biogen

Illumina

iShares Nasdaq Biotechnology ETF

IBB tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges.

iShares U.S. Medical Devices ETF

Vanguard Health Care ETF

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

These exchange-traded funds offer investors an easy way to potentially profit from growth in the healthcare sector.

5 Top Healthcare ETFs

Shares of Biogen Inc. rocketed higher on Tuesday, headed for their strongest performance in 20 years, after the biotechnology company surprised investors by stating that its Alzheimer’s treatment was prepared to start the regulatory approval process, as well as from third-quarter earnings that handily beat expectations.

Biotech ETF Rallies on Alzheimer Treatment News

The iShares Nasdaq Biotechnology ETF (IBB), the largest biotech-related ETF by assets, closed lower last Friday, but for the week, the fund gained 2%. That could be a sign downtrodden biotech ETFs are poised to bounce back.

It Could be to Time to Bank on Biotech ETFs

The healthcare sector, led by ETFs like the SPDR Health Care ETF (XLV), is helping to drive stocks higher on Tuesday, along with technology. XLV is up over 1.67%, as reported earnings from several major healthcare companies are driving stock prices up.

Market Charges Higher Led By Healthcare Sector

Investors continued to yank money out of biotechnology sector-related ETFs for the seventh consecutive week, the longest back-to-back weekly selling since late 2017. According to PiperJaffray analyst Christopher Raymond’s weekly note, investors withdrew money out of healthcare/biotech-specific funds, Barron’s reports.

Biotech ETFs Suffer Seventh Week of Outflows

Invesco Dynamic Biotechnology & Genome ETF

Many biotech ETFs and other funds have fallen sharply off their highs in recent months.

Investors flee Biotech ETFs as they Lag Bull Market

VanEck Vectors Biotech ETF

Amid intensifying scrutiny of drug pricing and other political pressures, biotechnology ETFs and active mutual funds endured some rough sledding in the third quarter. The iShares Nasdaq Biotechnology ETF (IBB), VanEck Vectors Biotech ETF (BBH) and the equal-weight SPDR S&P Biotech ETF (XBI) are all saddled with third-quarter losses and data suggest investors have been fleeing [.

Biotech ETFs Had A Rough Third Quarter

Healthcare and biotechnology-related ETFs are taking a blow as drug-pricing reforms weigh on the sector outlook. The Health Care Select Sector SPDR ETF (NYSEArca: XLV) fell another 0.6% and the iShares Nasdaq Biotechnology ETF (IBB)  declined 2.0% in back-to-back selling on Thursday.

Drug Pricing Reforms Keep Pressure on Biotech, Healthcare ETFs

Virtus LifeSci Biotech Products ETF

First Trust NYSE Arca Biotechnology Index Fund

ALPS Medical Breakthroughs ETF

While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength from an unexpected surge in ACADIA Pharmaceuticals (NasdaqGS: ACAD), following the biopharma company’s positive announcement for a phase 3 trail on dementia-related psychosis.

ACADIA Pharmaceuticals Help Lift Biotech ETFs

iShares Evolved U.S. Innovative Healthcare ETF

Invesco Dynamic Pharmaceuticals ETF

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

Amgen to Buy Celgene's Otezla: 5 ETF Drugs

Late Monday, a U.S. District Court overturned President Trump's requirement that pharmaceutical companies and biotech stocks list the prices of their medicines in TV ads.

Drug Pricing War: Pharma, Biotech Stocks Score A Win Over Trump

Pfizer's deal to buy Array BioPharma for $10.6 billion has ignited biotech stocks. There are ways to get in on the rally using exchange-traded funds.

Biotech ETFs are breaking out—here are 3 ways to play the space

Institutional players are abandoning biotech funds at a rapid pace, raising the odds that the sector will enter a bear market.

Biotech Sector Could Enter Bear Market

ARK Genomic Revolution Multi-Sector ETF

Bristol-Myers

Celgene

Direxion Daily S&P Biotech Bull 3X Shares

When the stock market is hitting record highs, it’s important to remember that it’s really a market of stocks rather than a stock market. Not all companies are created equal. Nor are all sectors.

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

Fidelity MSCI Health Care ETF

Health care's sharp drop comes as investors worry that left-leaning policy ideas like universal health coverage are gaining support.

News for iShares Nasdaq Biotechnology ETF ETF (IBB)